Yes. Thanks, Gene. And good morning, Jeff, sure. So when you step back and look at the relationship between CV growth and revenue, obviously, in a steady-state environment, those two things are pretty close. But when we look at our last couple of years, in 2020, CV grew 4% but Research revenue - or actually, Research revenue in 2021 grew 13%. CV in 2021 grew 16%, and we're guiding to Research revenue growth of 12% FX neutral. Again, as I mentioned, in a typical steady-state environment, CV and the following year research growth rates will generally be similar, not necessarily right on top of each other but relatively similar. As we look at 2022, most but not all of our 2022 revenue dollars are driven by our year-end 2021 contract value dollars. As we mentioned in the prepared remarks and as you alluded to, 2021 did benefit from the tenure mix, the NCVI phasing, not only the quarterly NCVI phasing but the NCVI phasing within the months of the quarter. We had record retention rates. And we also mentioned really, really strong non-subscription growth. And so all those things worked in our favor to get a pretty strong revenue yield in fiscal year 2021. And we're not assuming all of those persist at the same levels that we saw in 2022. And so while CV growth in '21 was at the high end of our medium-term guidance, we're not assuming that we stay all the way at the top of that medium term guidance. And so essentially, what we've done is we've taken a balanced approach based on historical trends and patterns, and we've reflected that in the guidance. As we mentioned, our teams are focused on driving growth that's faster than what's embedded in the guidance. And as we also mentioned in our prepared remarks, if we do perform closer to those 2021 levels on retention rates, NCVI phasing, et cetera, there can potentially be upside to the initial guidance as well.